Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Abstract Text:

ADAPT Research Group,C G Lyketsos,J C S Breitner,R C Green,B K Martin,C Meinert,S Piantadosi,M Sabbagh,

OBJECTIVE: To evaluate the efficacy and safety of naproxen and celecoxib for the primary prevention of Alzheimer disease (AD). METHODS: Randomized, placebo-controlled, double-masked clinical trial conducted at six US dementia research clinics. Volunteers aged 70+ years, with cognitive screening scores above designated cut-offs and a family history of AD, were randomly assigned to celecoxib 200 mg BID, naproxen sodium 220 mg BID, or placebo. Enrollment began in early 2001. The main outcome measure was diagnosis of AD after randomization. RESULTS: On December 17, 2004, treatments were suspended. Events while on treatment yielded hazard ratios vs placebo of 1.99 (95% CI 0.80 to 4.97; p = 0.14) for celecoxib and 2.35 (0.95 to 5.77; p = 0.06) for naproxen. Imperfect screening measures led to enrollment of 7 individuals with dementia and 46 others with milder cognitive syndromes. Their (prevalent) illness was detected at enrollment and diagnosed within 6 months following randomization. Secondary analyses that excluded the 7 cases of prevalent dementia showed increased hazard ratios for AD with both treatments. Neither treatment produced a notable effect on the incidence of milder cognitive syndromes. CONCLUSIONS: These results do not support the hypothesis that celecoxib or naproxen prevent Alzheimer dementia, at least within the early years after initiation of treatment. Masked long-term follow-up of these participants will be essential.

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Publishing Authors By Initials

ADAPT Research Group,CG Lyketsos,JC Breitner,RC Green,BK Martin,C Meinert,S Piantadosi,M Sabbagh,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Neurology

VOLUME: 68

Page Numbers: 1800-8

Journal Abbreviation: Neurology

ISSN: 1526-632X

DAY: 25

MONTH: 04

YEAR: 2007

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 401060

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: adverse effects

Chemical & Substance for Abstract: Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Information

Substance Name: Naproxen

Registry Number: 22204-53-1

Grant and Affiliation Information for Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

AFFILIATION: Johns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, MD 21224, USA.

Country: United States

AGENCY: United States NIA

GRANT: U01 AG15477

ACRONYM: AG

MEDLINETA: Neurology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Related Publications

• A method for optimising excision of the nail bed matrix.
• Certain anesthetic procedures in bronchopleuropulmonary suppurations
• Challenges to the recognition and assessment of Alzheimer's disease in American Indians of the southwestern United States.
• Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics".
• Detecting Alzheimer disease before it happens: The key to prevention?
• ECT and the media.
• ECT and the media.
• Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.
• HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.
• How to do it . . . Appear on television.
• Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk.
• Lipoma of the uterus.
• Momentum-Transport Studies in High ExB Shear Plasmas in the National Spherical Torus Experiment.
• Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
• Pathological correlates of cognitive decline in Alzheimer's disease.
• Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes.
• Postgraduate education and the doctor.
• Progressive aphasia with Lewy bodies.
• Salmonella typhi in a child with urinary tract infection and urolithiasis.
• Selective dorsal rhizotomies in the treatment of spasticity related to cerebral palsy.
• Theory of mind development in Chinese children: A meta-analysis of false-belief understanding across cultures and languages.
• [Anti-inflammatory activity of a copper complex carrying a sugar vector, and observed serum copper levels]
• [Bleedings in the early pregnancy in a total material of 48017 deliveries. Statistical evaluation]
• [Exploration of pulmonary function.]
• [Gauze plate support in thoracoplasty.]
• [Radiological & bronchographic aspects of bronchopulmonary cancer.]
• [TREATMENT OF TRACHOMA AND PANNUS WITH GANTRISIN IN THE SERVICE D'OPHTALMOLOGIE DE LA FACULT'E DE M'EDECINE DE DAMAS.]